NEW DELHI: Biotechnology main Biocon has reported an 18.97 per cent fall in consolidated revenue at Rs 186.6 crore for the quarter ended December 31, 2020 on account of upper bills. The corporate had posted a revenue of Rs 230.three crore for the corresponding interval of the earlier fiscal.

The corporate’s income from operations rose to Rs 1,851 crore for the quarter into consideration, up 7.81 per cent, as towards Rs 1,716.Eight crore throughout the identical interval a yr in the past, Biocon stated in a late evening regulatory submitting on Thursday.

Bills rose to Rs 1,642.6 crore for the December quarter, a rise of 14.52 per cent, as towards Rs 1,434.three crore within the year-ago interval.

Kiran Mazumdar-Shaw, Government Chairperson, Biocon, stated: “2020 has been probably the most difficult years for the world with an unprecedented pandemic impression on the worldwide economic system. We proceed to face headwinds throughout operational, regulatory and industrial capabilities which have been deterrents to our deliberate market growth. Nevertheless, we count on normalisation by subsequent fiscal”.

Shares of Biocon Ltd had been buying and selling 8.44 per cent decrease at Rs 404.64 apiece on the BSE.

LEAVE A REPLY

Please enter your comment!
Please enter your name here